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doi:10.1016/j.ejvs.2010.06.014Abstract Background: A possible mechanism underlying cardiovascular morbidity after
major vascular surgery may be the perioperative ischaemiaereperfusion with excessive
oxygen-derived free-radical production and increased levels of circulating inflammatory medi-
ators. We examined the effect of melatonin infusion during surgery and oral melatonin treat-
ment for 3 days after surgery on biochemical markers of oxidative and inflammatory stress.
Methods: Patients received an intra-operative intravenous infusion of 50 mg melatonin or
placebo. In addition, all patients received 10 mg melatonin or placebo orally the first 3 nights
after surgery. Blood samples for analysis of malondialdehyde (MDA), ascorbic acid (AA), dehy-
droascorbic acid (DHA) and C-reactive protein (CRP) were collected preoperatively, and at
5 min, 6 h and 24 h after clamp removal (recirculation of the first leg).
Results: Twenty-six patients received melatonin and 24 patients received placebo. No signifi-
cant differences were observed in any of the oxidative and inflammatory stress parameters.
There were significantly more side effects in the melatonin group than in the placebo group.
Conclusions: Melatonin treatment in the perioperative period did not reduce the oxidative and
inflammatory parameters measured in this study.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Aortic-aneurysm surgery is associated with considerable
perioperative cardiovascular complications such as
myocardial infarction, pulmonary oedema, arrhythmias and88 44 88.
Go¨genur).
ty for Vascular Surgery. Publishediminished cardiac output.1e3 A possible mechanism may
be tissue injury after ischaemiaereperfusion injury with
excessive oxygen-derived free-radical production andd by Elsevier Ltd. All rights reserved.
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Oxygen-derived reactive molecules attack membrane
lipids, resulting in membrane dysfunction and, subse-
quently, cellular dysfunction that has been suggested to
contribute to postoperative organ injury or failure.1,4,5 A
situation with production of reactive molecules exceeding
the mechanisms required to detoxify them is referred to as
oxidative stress. Elimination of oxygen-derived reactive
molecules with antioxidants during ischaemiaereperfusion
injury may improve prognosis in patients undergoing major
vascular surgery.1,4e7
Melatonin, the chief secretory product of the pineal
gland, is an efficient scavenger of reactive molecules, and
is more effective than the well-known classical antioxi-
dants, vitamins C and E.8,9 In both in vivo and in vitro
studies, melatonin has been reported to prevent ischae-
miaereperfusion injury, which is suggested to be related to
its antioxidant properties.10e12 Melatonin has only been
used in few human surgical trials, showing a modification of
the oxidative stress response in neonates with surgical
malformations.13 Intravenous melatonin infusion in doses
between 10 and 60 mg, during abdominal aortic-aneurysm
repair, has previously been shown to be without immediate
toxic reaction,7 but there are no data on the effect on
oxidative stress response to surgery.
It is difficult to perform a direct measurement of
oxygen-derived free radicals in plasma. An alternative
method is to measure the by-products after oxidative
attack on lipids and proteins. Malondialdehyde (MDA) is
a low-molecular-weight aldehyde that is produced after
free-radical attack on polyunsaturated fatty acids (e.g.,
arachidonic acid). Ascorbic acid (AA) is a very potent intra-
and extracellular antioxidant, scavenging oxygen-derived
free radicals and can be measured in plasma. Dehy-
droascorbic acid (DHA) is the oxidised form of AA.
Measurement of products of lipid peroxidation and antiox-
idants in relation to surgery for abdominal aortic aneurysm
have shown to correlate to postoperative cardiovascular
morbidity.1,4
In this blinded, randomised, placebo-controlled trial, we
examined the effect of melatonin on markers of oxidative
and inflammatory stress response after elective abdominal
aortic-aneurysm repair.Methods
The trial was conducted as a randomised, placebo-
controlled, double-blinded study. Each patient was
randomly assigned to receive either melatonin or placebo,
and randomisation was made by computer-generated block
randomisation with 26 patients in each block. Written
informed consent was obtained from all patients, and the
Ethics Committee, the Danish Data Protection Agency and
the Danish Medicines Agency approved the study. Further-
more, the study was monitored by the Good Clinical Prac-
tice (GCP) unit at Copenhagen University Hospital and was
registered at www.clinicaltrials.gov (NCT00315926).
Patientswere included if agewas between 18 and 80 years
and undergoing elective open abdominal aortic-aneurysm
repair or aortobifemoral bypass surgery. Exclusion
criteria were: American Society of Anesthesiologist (ASA)physical-status classification > III, current anticoagulation
therapy with warfarin or phenprocoumon, anything other
than sinus rhythm on preoperative 12-lead electrocardiog-
raphy (ECG), renal insufficiency (plasma urea>200 mmol l1)
or hepatic insufficiency (medical history of chronic liver
disease), continuous medication for psychiatric disease,
regular medication with opioids and benzodiazepines,
alcohol abuse, insufficient compliance (not able to under-
stand written or spoken Danish, psychiatric diseases and
dementia), pregnancy or breast feeding and lack of written
informed consent.
Because of the elective surgical procedure, all patients
were admitted to the hospital the day before surgery. All
patients were asked about any side effects to treatment
(headache, confusion, depression and dizziness or other
unexpected symptoms) for 4 days after surgery. During the
study, all patients received general anaesthesia, according
to the standards of the anaesthesiology department. b-
Blocker treatment was continued in all patients receiving
preoperative b-blocker treatment. Two hours before the
surgical intervention, all patients received 1200 mg of
gabapentin. Patients received an epidural catheter for
intra- and postoperative epidural blockade induced with
a bolus injection containing 3 ml of 2% lidocaine with
adrenalin and 5e8 ml of 0.5% bupivacaine. Epidural
blockade was maintained during the operation with a 0.5%
bupivacaine infusion of 4 mlh1. After end of operation, the
epiduralanalgesic regimen comprised 50 mgml1 morphine
and 2.5 mgml1 bupivacaine with an infusion rate of
4 mlh1. The epidural infusion was maintained until 3 days
after surgery. Anaesthesia was induced by 3e5 mgkg1 of
thiopental, 0.2e0.4 mg of fentanyl, 1.5e2.5% sevoflurane
and 0.6 mgkg1 of rocuronium. General anaesthesia was
maintained with fentanyl, sevoflurane and rocuronium.
Fifteen grams of mannitol and 1.5 g of cefuroxime were
administered during surgery. Immediately before the
expected end of surgery, patients with continued muscle
relaxation were given 0.5 mg of glycopyrron and 2.5 mg of
neostigmine. All patients had a bladder catheter until the
first postoperative day. All patients were allowed full oral
nutrition and were fully mobilised from the day of surgery
until discharge.
Patients were extubated after surgery and only contin-
uously intubated until admission to the surgical intensive
care unit (ICU) if they had a central temperature below
35.5 C at the end of surgery. Intubated patients received
100e150 mgh1 of propofol and 0.05e0.1 mg of fentanyl.
Extubated patients received either 0.05e0.1 mg of fentanyl
or 2.5e10 mg of morphine for rescue analgesia. Further-
more, the analgesic regimen comprised 4 g day1 of para-
cetamol and 1200 mg day1 of gabapentin. At the ICU, the
patients were monitored continuously with telemetry,
blood pressure, mean arterial blood pressure, pulse rate,
temperature and oxygen saturation measurements. The
assessments were performed until discharge to the general
surgical ward.
The study medication was chromatographically pure
(Helsinn Chemical Co, Biasca, Switzerland) and was tested
for sterility according to the European Pharmacopoeia
requirements. Immediately before the start of the surgical
procedure, melatonin was dissolved in a 2:23 mixture of
ethanolephysiologic saline. The patients received the study
Figure 1 CONSORT diagram showing the flow of the patients
through each stage of the randomised trial.
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ethanolephysiologic saline) intravenously as a continuous
infusion for 2 h, starting from the first incision. All patients
also received either 10 mg melatonin (Penn Pharmaceutical
Services Limited, Tredegar, Gwent, Wales, UK) or 10 mg
placebo (lactose) orally the first 3 nights after surgery
at 22:00.
Blood samples for analysis of MDA, AA, DHA and
C-reactive protein (CRP) were collected the day before
operation and at 5 min, 6 h and 24 h after clamp removal
(recirculation of the first leg). CRP was also collected at 48,
72 and 96 h after clamp removal.
Blood samples for DHA and AA analysis were collected in
tubes with an anticoagulant and centrifuged immediately
after collection and an aliquot was directly mixed with 10%
meta-phosphoric acid containing 2 mM disodium ethyl-
enediaminetetraacetic acid (EDTA). The precipitate was
removed by centrifugation, and the samples were imme-
diately frozen on dry ice and, within few minutes, stored at
80 C until analysis. AA and DHA were analysed in meta-
phosphoric acid-stabilised EDTA-plasma. High-performance
liquid chromatography (HPLC) with coulometric detection
was used for AA and DHA analysis as published else-
where.7,14,15 Thoracic aortic aneurysm (TAA) was assessed
after reduction with tris[2-carboxyethyl]phosphine hydro-
chloride, and DHA was calculated from the difference
between AA and TAA (AA þ DHA).16 MDA samples were
stored at 80 C until analyses with HPLC with fluorescence
detection, as described previously.7,17
CRP was analysed using an immunoturbidimetric assay
(Cobas Integra 400, Roche Diagnostics A/S, Hvidovre,
Denmark) with a lower detection limit of 0.71 mgl1.
Aldrete standard sedation criteria were used to register
the sedation level immediately after the operation ended
and at admission to the ICU.18 Sedation was graded at a 0e3
point scale with 0 indicating awake and lucid and 3 indi-
cating always sleeping and/or not possible to be awake.
Pre- and intra-operatively, mean arterial blood pressure
(MAP) and pulse rate were assessed non-invasively every
15 min for 135 min, immediately before the surgical inci-
sion. Furthermore, levels of MAP and central body
temperature in the postoperative phase were assessed
immediately after surgery at admission to the ICU and,
then, 20 h thereafter.
When the studywasdesigned, therewereno studies to our
knowledge wherein the primary effect parameter, MDA, was
analysed in relation to abdominal aortic-aneurysm surgery.
The statistical power analysis was based on the study by
Zulfikaroglu et al.,l9 where the mean MDA (standard devia-
tion (SD)) concentration in blood, 30 min after open chole-
cystectomy, was 50.2 mmol l1 (30.8). The minimal relevant
difference was set to 50% for MDA as the primary effect
parameter. With a type 1 error of 5% and power of 80%, the
number of patients needed in the studywas 23 in each group.
We decided to include 24 patients in each group.
Data are reported as mean (SD) unless stated otherwise.
TheKolmogoroveSmirnof testwas used to check normality of
distribution. Repeated-measures analysis of variance
(ANOVA) was used with time as a within-subject parameter
and treatment group (melatonin or placebo) as a between-
subjects parameter. Independent-sample t-test was used
to estimate the differences between the groups incontinuous data regarding patient characteristics. In addi-
tion, chi-square test was used for categorical variables and
Fisher’s exact test for dichotomous variables. Bonferroni
correctionwasmade to compensate formultiple testing. A P-
value <0.05 was considered statistically significant. Statis-
tical Package for the Social Sciences program (SPSS) version
17.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis.
Results
A total of 52 patients were randomly assigned to melatonin
or placebo treatment during elective major vascular
surgery between April 2007 and September 2008 (Fig. 1).20
Because extended surgery with nephrectomy was decided
immediately before incision, one patient in the placebo
group did not receive the allocated intervention. Further-
more, one patient in the placebo group was excluded
because of perforation of the colon during the operation.
Table 1 shows demographic variables and baseline
characteristics indicating no differences in age, body mass
index (BMI), ASA score, blood pressure, pulse rate levels
and temperature. There were significantly more female
patients in the placebo group (Fisher’s exact test,
PZ 0.047). Duration of anaesthesia, surgery and ischaemia
period was not different between the two groups (Table 1).
No differences in loss or replacement of fluid and blood
were found between the two groups (Table 1).
Plasma MDA concentrations significantly decreased over
time for the whole study group (repeated-measures ANOVA,
P < 0.0001), but there were no differences between the
melatonin and placebo groups (repeated-measures ANOVA,
PZ 0.50) (Fig. 2(a)). AA levels decreased significantly over
time for the whole study group (repeated-measures ANOVA,
P < 0.0001), but there were no differences between the






Age (years) 65 (11) 66 (10) 0.907
Gender (male/female) 15/9 23/3 0.047
BMI (kg/m2) 25 (4) 26 (4) 0.462
ASA (I/II/III) 0/16/8 1/20/5 0.357
AAA repair/Aorto-bifemoral bypass 20/4 22/4 1.0
Aneurism diameter (cm) 5.9 (0.8) 6.2 (1.1) 0.297
Tube/bifurcated grafts 15/9 18/8 0.767
Surgery duration (min) 164 (43) 158 (33) 0.599
Anaesthesia duration (min) 284 (27) 273 (30) 0.169
Ischaemia duration (min) 64 (22) 68 (24) 0.597
Fluid loss (ml) 696 (576) 700 (433) 0.979
Blood loss (ml) 1802 (1030) 2097 (1479) 0.409
Fluid replacement (ml) 4358 (1246) 4735 (1273) 0.286
Blood replacement (ml) 1192 (995) 1413 (1501) 0.535
Blood pressure the day before surgery
Systolic pressure (mmHg) 145 (19) 149 (19) 0.396
Diastolic pressure (mmHg) 84 (16) 89 (15) 0.260
Intraoperatively
Pulse rate level (bpm) 68 (8) 72 (9) 0.058
Mean arterial blood pressure (mmHg) 73 (6) 74 (7) 0.552
Postoperatively
Mean arterial blood pressure (mmHg) 83 (10) 80 (8) 0.248
Temperature 37.1 (1.1) 37.4 (0.8) 0.277
Aldrete sedation score (0/1/2/3) 9/7/2/6 10/10/1/5 0.629
Side effects
Headache/Confusion/Depression/Dizzines 1/0/0/1 0/3/1/5 0.04
ASA: American Society of Anesthesiologist (ASA) physical-status classification; BMI: body-mass index (kg/m2). Data are shown as mean
(SD). Bpm: beats per minute. *: Duration of aortic cross-clamping. Postoperatively: Mean arterial blood pressure and temperature
assessments until 24 h postoperatively.
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PZ 0.051) (Fig. 2(b)). DHA levels were unchanged over the
study period (repeated-measures ANOVA, P Z 0.15) and
also did not differ between the placebo and melatonin
groups (repeated-measures ANOVA, P Z 0.10) (Fig. 2(c)).
There was a significant decrease in CRP levels 5 min after
reperfusion and a significant increase at 24, 48, 72 and 96 h
after reperfusion (repeated-measures ANOVA, P < 0.001 for
all measurement points), but no differences were observed
between the melatonin and placebo groups (repeated-
measures ANOVA, P Z 0.355) (Fig. 3).
Aldrete sedation scores on arrival at the ICU were not
different between the two groups (Table 1). All patients were
extubated on the day of the surgery. Therewere no significant
differences between the groups with respect to surgery-
related complications. There were more side effects in the
melatoningroup than in theplacebogroup,PZ0.04 (Table1).Discussion
In this prospective, randomised, double-blinded, placebo-
controlled trial, we found no significant differences in surro-
gatemarkers of oxidative and inflammatory stress parameters
between the melatonin and placebo groups.Surgery for abdominal aortic aneurysm is followed by
significant morbidity and mortality with a 4e7% incidence
of myocardial infarction and 12e36% cardiac complications
without evidence of ischaemic damage.1 The ischae-
miaereperfusion injury during major vascular surgery is
partly mediated by excessive free-radical production. The
degree of free-radical production is reported to correlate
with the release of the myocardial injury marker troponin.1
Wijnen et al.6 evaluated the effect of multi-antioxidant
supplementation (vitamins C and E, allopurinol, N-ace-
tylcysteine and mannitol) in patients undergoing abdominal
aortic-aneurysm surgery. They administered vitamin C 5
days prior to the operation. Vitamin E was administered on
the morning of the operation. Allopurinol was administered
1 day before the operation and intravenously before the
start of the operation. N-acetylcysteine was administered
before the start of the operation and, subsequently, in
a drop over 12 h. Mannitol was administered for 12 h
starting at the beginning of surgery. They measured white-
blood-cell count, serum creatine kinase, aspartate amino-
transferase, lactate and lipofuscin before the start of the
antioxidant therapy, before clamping and after release of
the clamp, 5 min after release of the first leg, during
closure of the skin, 6 h after release of the first clamp and
24 and 48 h after surgery. The effect of antioxidants was
Figure 2 Mean (bars SE) malondialdehyde (MDA, mmol/L) (Fig. 2a), ascorbic acid (AA, mmol/L) (Fig. 2b) anddehydroascorbic acid
(DHA,mmol/L)(Fig. 2c) levels for the placebo (white columns) and melatonin (grey columns) group in the pre-, intra- and post-
operative phases. Preop: preoperatively; 5 min: 5 min after clamp removal (recirculation of the first leg); 6 h: 6 h after clamp
removal (recirculation of the first leg); 24 h: 24 h after clamp removal (recirculation of the first leg); 48 h: 48 h clamp removal
(recirculation of the first leg); 72 h: 72 h clamp removal (recirculation of the first leg); 96 h: 96 h clamp removal (recirculation of
the first leg). No significant findings were observed between the two groups.
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tate aminotransferase, probably due to a reduction in
oxidative stress response and decreased leucocyte
sequestration and activation.6 In our study, the patients
were randomised to receive either 50 mg melatonin or
placebo as infusion for 2 h, starting from the first incision.
The aim was to establish supraphysiologic levels of plasma
melatonin during the surgical intervention, thereby opti-
mising the antioxidant capacity needed for a possible
modification of the oxidative/nitrosative stress response
and the degree of myocardial injury. We administered
melatonin intravenously to reach higher blood levels when
bypassing first-pass metabolism in the liver. We could not,however, show an effect on the biochemical markers of
oxidative stress and inflammation. The reason might be
that the dose we used was too low and that we did not
infuse melatonin for a longer duration of time. In the only
human study in patients undergoing surgery where oxida-
tive stress was measured, up to 10 doses of 10 mgkg1 were
used.13 In this case, the patients were newborn infants,
who had obviously much smaller body weights than the
patients in our study. Little is known about the optimal
duration of infusion and dose of melatonin in relation
to surgical stress. For ethical reasons, we previously per-
formed a dose-safety study to demonstrate that there were
no toxic effects of melatonin infusion (10e60 mg) in the
Figure 3 Mean C-reactive protein (CRP, mg/L) levels for the
placebo (dashed line) andmelatonin (full line) group in the pre-,
intra- and postoperative phases. Preop: preoperatively; 5 min:
5min after clamp removal (recirculation of the first leg); 6 h: 6 h
after clamp removal (recirculation of the first leg); 24 h: 24 h
after clamp removal (recirculation of the first leg); 48 h: 48 h
clamp removal (recirculation of the first leg); 72 h: 72 h clamp
removal (recirculation of the first leg); 96 h: 96 h clamp removal
(recirculation of the first leg). No significant findings were
observed between the two groups.
466 B. Ku¨cu¨kakin et al.intra-operative period.7 In the present study, there were
significantly more patients with headache, confusion,
depression or dizziness in the melatonin group than in the
placebo group.
Comparing to baseline values, there was a significant
decrease in MDA levels for both the groups 5min and 6 h after
clamp removal compared with preoperatively, but no
difference was observed between the groups. As expected,
we observed a decrease in AA at 5min, 6 and 24 h after clamp
removal, indicating an ongoing oxidative stress response and
increased turnover of AA. We observed stationary levels of
MDA and AA 6 h after clamp removal, but there was no return
of these values to preoperative levels in the measurement
period. The use of AA as an antioxidant could possibly explain
the decreased levels of MDA, indicating reduced lipid per-
oxidation. In addition, the unexpected reduction of the MDA
concentration after surgery could be caused by the antioxi-
dant effect of lidocaine, mannitol and propofol in our
study.21e28 In a study by Papalambros et al.,29 MDA levels
increased in 53 patients undergoing abdominal aortic aneu-
rysm. The pre-medication and general anaesthesia were not
described, but no patient received mannitol. In another
study30 with propofol and lidocaine intervention, no signifi-
cant changes in MDA were observed in patients undergoing
abdominal aortic-aneurysm repair.
Based on the lack of increase in MDA found in our study,
it is a limitation that we did not measure oxidative stress by
other markers. One alternative method could be the
measurement of the pro-oxidant potency of whole serum
assessed in human umbilical vein endothelial cells using
a fluorescent probe after stimulation by the plasma
collected at different time points.31
We observed an increase in CRP levels, a marker of
systemic inflammatory response, starting from 24 h afterreperfusion. The present study confirms the established
knowledge that surgical trauma induces major changes in
serum levels ofCRP.32 In spiteof thepreviously demonstrated
anti-inflammatory effects of melatonin, we did not observe
any differences between the placebo and melatonin groups.
This might be due to the early use of melatonin in the intra-
operative phase and the late production of CRP. Measure-
ment of an early inflammatory cytokine, for example, IL-6,33
would have provided valuable information regarding the
anti-inflammatory effect of melatonin within the first post-
operative day. Interestingly though, and in agreement with
a previous study, we found that the increase in CRP occurred
after the decline in AA, indicating that the latter was not
caused by the inflammatory activity, but might be affected
by other mechanisms.34
There were no significant differences between the two
groups in the amount of perioperative fluid or blood adminis-
tration; there were also no significant differences in the
amount of fluid loss and blood loss during surgery. Thus, a bias
with respect to haemodilution or uneven administration of
blood products cannot be expected to affect our results. Oral
uptake of melatonin (10 mg) in patients in the ICU has been
shown to be rapid and comparable with or even higher than
similar doses in healthy individuals.35 Thus, it can beexpected
that the oral uptake would be sufficient in our patient group.
In conclusion, we did not find any effect of melatonin on
biochemical markers of oxidative and inflammatory
stress parameters measured in this study; however, an
increased number of side effects were reported in the
melatonin group.
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